September 2021 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year (FY) 2023 Concepts

Asthma and Allergic Diseases Cooperative Research Centers

Request for Applications—proposed FY 2023 initiative

Gang Dong

Objective: Given the high prevalence of asthma and allergic diseases worldwide, this program aims to investigate mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goals of the program are to improve understanding of the pathogenesis of these conditions and to generate novel data that provide a rational foundation for new, effective treatments and/or disease prevention strategies.

Description: The initiative will support NIAID's unique and long-standing Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. This program funds research centers across the United States to conduct interdisciplinary and translational research in asthma and allergic diseases. The Centers coordinate their efforts through a Steering Committee and collaborate with one another through an opportunity fund that supports small, independent pilot studies.

This is a renewal initiative and no substantial change in the overall design or scientific goals is anticipated.

Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices

Broad Agency Announcement—proposed FY 2023 initiative

Anuj Patel

Objective: This broad agency announcement serves as the Radiation and Nuclear Countermeasures Program’s only mechanism to solicit investigator-initiated mid-stage research directed to investigational new drug application or investigational use only-enabling efforts for the development of countermeasures to treat acute radiation syndrome (ARS), and/or delayed effects of acute radiation exposure (DEARE). This mechanism can provide funding to investigators for further development of countermeasures and is complementary to the Product Development Support Services contract, which provides only services. This will give NIAID program staff more flexibility in advancing MCM development.

Description: This initiative will support the research and development of biodosimetry approaches to assess exposure level or MCMs to mitigate/treat ARS and DEARE.

Immune Drivers of Autoimmune Disease

Request for Applications—proposed FY 2023 initiative

Tom Esch

Objective: This initiative will improve our mechanistic understanding of the immunologic processes underlying the initiation, progression, and clinical course of autoimmune diseases in humans. The program will approach this objective via mechanistic, investigator-driven studies that test specific hypotheses regarding the course, progression, flare or relapse, remission, and/or clinical course of disease; and a collaborative, discovery-oriented, hypothesis-generating study of the initial transition from clinical health to the onset of autoimmune disease.

Description: The first component will be a set of investigator-defined projects aimed at defining the molecular events underlying flare, remission, and/or progression of autoimmune disease. It is expected that these projects will draw upon existing cohorts of subjects already diagnosed with autoimmune disease and will employ state-of-the-art techniques to identify molecular-level changes and the corresponding immunologic events that correspond with flare, remission, or progression of disease.

Investigators will form a cooperative group for exchange of concepts, techniques, and resources across projects to maximize their impact. All investigators who receive funding for this component will also make specific commitments, with corresponding budgetary support, for recruitment of at-risk individuals for the second component of the initiative. The second component will be the recruitment and study of a new cohort of subjects at risk of developing autoimmune disease. Longitudinal samples will be collected periodically by the subjects, and subjects will also be monitored for development of autoimmune disease. When autoimmune disease is diagnosed in a subject, the stored samples will be compared to still-healthy controls to reveal changes that presage the onset of disease. 

Accelerating Progress in Celiac Disease Research

Notice of Special Interest (NOSI)—proposed FY 2023 initiative

Annette Rothermel

Objective: This notice informs potential applicants to NIH of special interest in research on the etiology and pathogenesis of celiac disease, identification of therapeutic targets, and development of preventative or disease ameliorating therapies/strategies.

Description: This NOSI will support investigations focused on gaining understanding of the immune basis of celiac disease, as follows:

  • Determining mechanisms underlying loss of oral tolerance
  • Identifying triggers of autoimmunity in celiac disease
  • Strategies to eliminate and revert the pathogenic memory gluten-specific CD4 memory T cells
  • Defining the cellular circuits and mechanisms involved in tissue destruction
  • Identifying the role of microbiota in the loss of oral tolerance and tissue destruction
  • Finding immune modulating interventions and strategies to prevent celiac disease and/or restore tolerance
  • Identifying biomarkers to predict tissue destruction in celiac disease
  • Determining what makes gluten a harmful dietary antigen that can cause tissue destruction
  • Discovering what triggers development of inflammatory T helper-1 responses to a dietary antigen
  • Determining how tissue destruction is linked to loss of tolerance
  • Identifying pathogenic mechanisms shared between celiac disease and other complex immune disorders

Molecular and Genetic Characterization of Inborn Errors of Immunity

Notice of Special Interest (NOSI)—proposed FY 2023 initiative

Frosso Voulgaropoulou

Objective: The purpose of this funding opportunity announcement is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of inborn errors of immunity is essential for their diagnosis and prognosis, and developing precision therapeutics.

Description: This NOSI will support investigations on inborn errors of immunity/primary immunodeficiencies classified by the International Union of Immunological Societies as follows:

  • Immunodeficiencies affecting cellular and humoral immunity
  • Combined immunodeficiencies with associated or syndromic features
  • Predominantly antibody deficiencies
  • Diseases of immune dysregulation
  • Congenital defects of phagocyte number or function
  • Defects in intrinsic and innate immunity
  • Autoinflammatory disorders
  • Complement deficiencies
  • Bone marrow failure

The applications received through this NOSI will be reviewed by Center for Scientific Review standing study sections and will be supported using payline funds.

Content last reviewed on